ER-phagy mediates the anti-tumoral synergism between HDAC inhibition and chemotherapy

Abstract Background Histone deacetylase inhibitors (HDACi) are clinically approved drugs for the treatment of hematological malignancies synergizing with chemotherapy. However, despite the long history of HDACi, the mechanistic underpinnings of this synergism have remained unclear. Methods Using tra...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Felix J. Gössl, Pierfrancesco Polo, Frederik Helmprobst, André Menzenbach, Alexander Visekruna, Thomas M. Gress, Till Adhikary, Matthias Lauth
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-04-01
Serie:	Cell Communication and Signaling
Soggetti:	ER-phagy FAM134B RETREG1 HDAC inhibitors ER-stress Chemotherapy
Accesso online:	https://doi.org/10.1186/s12964-025-02198-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!